Clinical Trial Update: Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating bioequivalence of a single-dose liraglutide administered subcutaneously with two different pen-injectors; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• liraglutide (liraglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Metabolism and Nutrition Disorder, Obesity | Phase 1 | Status: COMPLETED